Company Filing History:
Years Active: 2003-2004
Title: **Pol-Henri W. Guivarc'h: Innovating Pharmaceutical Compositions for Cholesterol Management**
Introduction
Pol-Henri W. Guivarc'h is a distinguished inventor based in Quebec, Canada, with a significant contribution to the field of pharmaceutical innovations. He holds two patents that focus on improving the bioavailability and effectiveness of fenofibrate, a medication commonly used in the treatment of dyslipidemia and related conditions.
Latest Patents
Guivarc'h's latest patents reveal his expertise in pharmaceutical processes. The first patent, titled "Spray Drying Process and Compositions of Fenofibrate," introduces a novel spray drying technique for preparing pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This innovation not only enhances the preparation of powdered compositions but also leads to the creation of various dosage forms, including capsules, tablets, powders, granules, and dispersions. These formulations offer a significant advantage by minimizing variances in bioavailability among patients, regardless of their fasting status.
His second patent, "Fibrate-Statin Combinations with Reduced Fed-Fasted Effects," describes an orally administered pharmaceutical composition that combines a statin with fenofibrate. This groundbreaking invention ensures that a greater percentage of fenofibrate is available to fasted human patients compared to those who have consumed a high-fat meal, thus optimizing treatment for elevated cholesterol levels.
Career Highlights
Throughout his career, Pol-Henri W. Guivarc'h has worked with notable companies such as RTP Pharma, Inc. and Skyepharma Canada, Inc., where he has contributed to the development of innovative pharmaceutical solutions. His work has significantly impacted the pharmaceutical industry, especially regarding formulations that aid in cholesterol management and improve patient outcomes.
Collaborations
In the course of his professional journey, Guivarc'h has collaborated with respected peers including Robert A. Snow and Indu Parikh. These collaborations have enriched his research and have led to advancements in pharmaceutical inventions that address complex medical challenges.
Conclusion
Pol-Henri W. Guivarc'h exemplifies the essence of innovation within the pharmaceutical industry. His patents not only enhance existing treatments for cholesterol-related conditions but also illuminate the path for future research in drug formulation. His contributions are vital in addressing health issues affecting millions and underscore the importance of ongoing innovation in medicine.